Pharmacy Times August 12, 2024
Investigators find that this could suggest the biosimilar uptake alone may not be a complete measure of the market competition and lowering prices.
The average sales price of both originators and biosimilars declined significantly after the introduction of biosimilars, according to a study published in Health Affairs Scholar. Investigators found that this could suggest the biosimilar uptake alone may not be a complete measure of the market competition and lowering prices.1
The global biosimilar market is projected to reach approximately $92 billion by 2031, after generating $27.3 billion in 2023. The fields projected to see the greatest growth are oncology biosimilars and diabetic insulin biosimilars. The increase in diagnoses in oncology has led to more investments into cancer research and...
Today's Sponsors
Today's Sponsor